- September 12 - 13, 2023
- - ET
- - ET
- Sponsored By:
2023 Scientific Computing Days
Sharing and Collaboration in the Data Multiverse:
Scientific Computing for Public Health Solutions
September 12, 2023 (9:00AM – 3:00PM ET)
September 13, 2023 (9:00AM – 4:30PM ET)
* In Person & Virtual
10903 New Hampshire Ave
Silver Spring, MD 20903
Building 31, Great Room
Co-Hosts & Collaborators
FDA Scientific Computing Board (SCB)
Center for Tobacco Products (CTP)
National Center for Toxicological Research (NCTR)
National Cancer Institute (NCI)
Matt Hartog, PhD (FDA/CTP)
Denny Skiles (FDA/NCTR)
The FDA Scientific Computing Board is a group of scientists and IT specialists at FDA who advocate for scientific computing needs, and requirements to advance FDA’s scientific and regulatory mission. The 11th annual Scientific Computing Days symposium is a conference promoting the latest advances in scientific computing technologies. The event’s goal is to help FDA improve the application of technology and scientific computing in support of the FDA’s public health mission. This year’s theme is “Sharing and Collaboration in the Data Multiverse: Scientific Computing for Public Health Solutions.”
* Additional event information will be provided in the upcoming months.
|Day 1: September 12, 2023|
|9:00AM – 9:05AM||
Denny Skiles is a Senior Executive with the National Center for Toxicological Research in Jefferson Arkansas. Denny joined FDA in 2022, coming from USDA as Director of the Geospatial Enterprise Operations (GEO) Center. While at GEO, Denny’s geospatial science team developed the Land Change Analysis Tool. This AI/ML technology assisted in spatial and temporal image analytics – highlighting land use changes from millions of land images in less than 1% of the normal time necessary for human review. This technology spread into a joint USDA/FAA project where it has been helpful in identifying potential bird strike-hazard areas, supporting safer commercial air travel. While not an “IT guy” by trade, Denny continues to be fascinated by the evolution of technology and the people that are not afraid to push the digital envelope.
|9:05AM – 9:25AM||
As the Chief Data Officer of the FDA, Ram C Iyer has the accountability to develop and execute an agency wide data modernization strategy, building robust central functions that can be leveraged by the centers and the agency for high value decisions. The scope spans the entire stack from data identification to actionable decision, including data policies and governance. Ram is an industry and peer recognized data and technology professional with experience in the Pharma, Consulting, Telecom and International Government organizations. His expertise includes Data and Decision Sciences, Digital and Technology Architecture, and Talent Development with a focus on building collaborative partnerships and Ecosystems. Before joining the FDA, Ram was the Head of Enterprise Architecture and Executive Director of Analytics Center of Excellence at Bristol Myers Squibb (BMS). He helped jumpstart several Data and Analytic practices at BMS including enterprise class platforms for reproducible research, model management and visual analytics. He also built a thriving network of data scientists, data analysts, visual story tellers, and agile specialists to tackle urgent and complex problems in the organization.
|9:25AM – 10:00AM||
Greg Singleton is a mission driven leader and technology expert that serves as the Chief Artificial Intelligence Officer (CAIO) for the US Department of Health and Human Services (HHS). In this role Greg leads efforts to promote strategic applications of AI and coordinates implementation of the Departmental AI strategy. Prior to his current role as CAIO, Greg served as the Program Manager for many of the national COVID-19 data systems. Originally from Ohio, Mr. Singleton graduated from the University of Virginia with a Bachelor of Science in Systems Engineering, and received Master of Science degrees in Political Science and Technology and Policy from the Massachusetts Institute of Technology.
|10:00AM – 10:15AM||
|10:15AM – 12:00PM||
Artificial Intelligence’s Impact on FDA
This breakout session will deal with three different, exciting AI topics. The first will be a talk about generative AI and provide use cases on how government agencies are using this approach to improve on how internal work is done. The second presentation will discuss the concept of using sensor-less (i.e. publicly available location and meteorological data) to model the climate inside a container to identify food quality degradation during transport. The third seminar will show how advances in machine learning and AI will impact the 3Rs and toxicology.
|12:00PM – 1:00PM||
|1:00PM – 2:30PM||
Large Language Models in Play
Join us for an extraordinary session that delves into the transformative realm of Large Language Models (LLMs) and their involvement in critical clinical decision-makings, review processes, and relevant computational technologies. This session brings together three distinguished speakers to explore cutting-edge advancements and applications in the fields of healthcare, regulatory review, and beyond. It will offer expert insights, real-world success stories, and a glimpse into the latest technologies propelling LLMs to new heights.
|2:30PM – 2:40PM||
|Day 2: September 13, 2023|
|9:00AM – 9:10AM||
Matt Hartog, PhD
Matt Hartog is a toxicologist within the Division of Nonclinical Science, Office of Science, at the Center for Tobacco Products. Matt joined CTP and the FDA in 2020 and is involved in the review of tobacco product applications and researching the toxicological properties of tobacco products. He has extensive experience in studying the toxicological mechanisms of inhaled chemicals and in using computational methods to identify susceptible populations/groups and evaluate the human health risks associated with chemical exposures. Prior to joining the FDA, he worked at the United States Army Medical Research Institute of Chemical Defense where he used omics-based technology and computational methods to characterize the toxicity of inhaled chemicals and identify potential medical countermeasures for exposure.
|9:10AM – 9:30AM||
Nelson A. Colón, PhD
Nelson Abdiel Colón Vargas is a Mathematician and AI Leader with a passion for Education, Equity and Civic Tech, and more than ten years of experience ranging from Academia, Startups, Fortune 100 companies, and the Federal Government. Prior to joining FDA as the AI/ML Lead in June 2023, Nelson served for three years as an Entrepreneur In Residence with the White House Presidential Innovation Fellows driving AI Innovation at VA, NSF, DOT and OSTP, followed by two years as a Digital Service Expert in AI/ML with the United States Digital Service (OMB/EOP) at the White House and the Defense Digital Service (CDAO/DOD) building AI/ML driven products as well as internal technical teams and communities to support them. He received a Special Act Award for the development and deployment of the Claims Attributes API, the first AI driven API deployed internally at the Department of Veterans Affairs which reduced cost of processing claims to the agency by 10 million dollars a year and reduced the wait time for Veterans by 7 days. Outside of government, Nel is also an Adjunct Faculty at the School of International and Public Affairs at Columbia University where he teaches students how to leverage Data Science for policy making.
|9:30AM – 10:00AM||
Jaime M. Guidry Auvil, PhD
Dr. Jaime M. Guidry Auvil currently serves as the Director of the Office of Data Sharing (ODS) within the National Cancer Institute (NCI). In her role, Dr. Guidry Auvil oversees the NCI strategy and approach to development, interpretation and implementation of data sharing and public access policies to enhance NCI mission in the wider cancer research and care community. Since joining NCI in 2010, Dr. Guidry Auvil has led critical, high profile data sharing initiatives for NCI and NIH, including large-scale pediatric cancer research through Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiative, Gabriella Miller Kids First Pediatric Research Program, and current flagship program for NCI, the Childhood Cancer Data Initiative (CCDI). Dr. Guidry Auvil is well-published and serves on several advisory committees within and across United States federal agencies, and international organizations, to provide expertise in optimizing data for cancer research. Dr. Guidry Auvil received her doctorate in Tumor Biology from Georgetown University, where she further holds a patent for a small molecule inhibitor targeting adhesion proteins in bone malignancies and metastases.
|10:00AM – 10:30AM||
|10:30AM – 12:00PM||
Open Ledger Technologies and Machine Readability in Regulatory Space
Open Ledger (also called “distributed ledger” or “shared ledger”) is a peer-to-peer digital information sharing framework that allows de-centralized sharing of synchronized digital data in geographically and/or otherwise distributed sites, countries, or institutions. In contrast to centralized databases, an open ledger does not require a central administrator, and consequently does not have a single point-of-failure. In this session we will discuss the potential, the advantages, and the disadvantages of the implementation of open ledger technologies in FDA regulated industries and at the FDA. We will discuss the role of open ledger technologies via information traceability, document sharing, machine readability, and information security.
|12:00PM – 1:00PM||
|1:00PM – 2:00PM||
Poster Session featuring Top 5 Scientific Computing Posters
|2:00PM – 2:15PM||
|2:15PM – 4:15PM||
This session, co-organized with the National Cancer Institute (NCI) Office of Data Sharing, will explore commonalities and unique differences of data management and sharing (DMS) along the scientific data life cycle at the FDA and NCI. With different missions of both agencies, FDA and NCI have distinct and overlapping priorities and considerations when it comes to the data sharing and public access; this session will help stakeholders better understand the landscape and terminologies from data generation, submission and sharing, to data access and factors to consider associated with these steps. The first two presentations will present an overview and introduce the OSTP Open Access Policy for all federal agencies. Then, there will be a more in-depth look at what the challenges and priorities for data submission and access are at NCI. Next, a series of presenters will highlight different aspects at the FDA – from receiving, to internal sharing, to external sharing of both regulatory and research data. Finally, we will share a success story of data access and sharing through precisionFDA challenges.
|4:15PM – 4:30PM||
Award Ceremony & Closing Remarks
Scientific Computing Innovator Award presented by FDA Chief Data Officer:
SCD Poster Session Contest Winners presented by SCD Co-chairs:
SCB Collaboration Awards presented by SCD Co-chairs:
SCB Leadership Awards presented by SCB Co-chairs:
|2023 SCD Event Program||pdf (5.27 MB)|